 Tissue Distribution
"Tissue Distribution" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
| Descriptor ID |
D014018
|
| MeSH Number(s) |
G03.787.917 G07.690.725.949
|
| Concept/Terms |
Tissue Distribution- Tissue Distribution
- Distribution, Tissue
- Distributions, Tissue
- Tissue Distributions
|
Below are MeSH descriptors whose meaning is more general than "Tissue Distribution".
Below are MeSH descriptors whose meaning is more specific than "Tissue Distribution".
This graph shows the total number of publications written about "Tissue Distribution" by people in this website by year, and whether "Tissue Distribution" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 2 | 2 | | 1981 | 0 | 2 | 2 | | 1982 | 0 | 3 | 3 | | 1983 | 0 | 2 | 2 | | 1984 | 0 | 3 | 3 | | 1985 | 0 | 4 | 4 | | 1986 | 0 | 2 | 2 | | 1988 | 0 | 3 | 3 | | 1989 | 0 | 5 | 5 | | 1990 | 0 | 6 | 6 | | 1991 | 0 | 5 | 5 | | 1992 | 0 | 4 | 4 | | 1993 | 0 | 11 | 11 | | 1994 | 0 | 12 | 12 | | 1995 | 0 | 11 | 11 | | 1996 | 0 | 6 | 6 | | 1997 | 0 | 5 | 5 | | 1998 | 0 | 4 | 4 | | 1999 | 0 | 11 | 11 | | 2000 | 0 | 12 | 12 | | 2001 | 0 | 7 | 7 | | 2002 | 0 | 10 | 10 | | 2003 | 0 | 10 | 10 | | 2004 | 0 | 11 | 11 | | 2005 | 0 | 12 | 12 | | 2006 | 0 | 9 | 9 | | 2007 | 0 | 8 | 8 | | 2008 | 0 | 5 | 5 | | 2009 | 0 | 4 | 4 | | 2010 | 0 | 6 | 6 | | 2011 | 0 | 4 | 4 | | 2012 | 0 | 6 | 6 | | 2013 | 0 | 7 | 7 | | 2014 | 0 | 11 | 11 | | 2015 | 0 | 6 | 6 | | 2016 | 0 | 4 | 4 | | 2017 | 0 | 5 | 5 | | 2018 | 0 | 2 | 2 | | 2019 | 0 | 5 | 5 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tissue Distribution" by people in Profiles.
-
Floege J, Funk F, Ketteler M, Rastogi A, Walpen S, Covic AC, Sprague SM. Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation. Nephrol Dial Transplant. 2020 06 01; 35(6):946-954.
-
Clark JW, Camidge DR, Kwak EL, Maki RG, Shapiro GI, Chen I, Tan W, Randolph S, Christensen JG, Ozeck M, Tang Y, Wilner KD, Salgia R. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
-
Marshall EL, Rajderkar D, Brown JL, Stepusin EJ, Borrego D, Duncan J, Sammet CL, Munneke JR, Kwan ML, Miglioretti DL, Smith-Bindman R, Bolch WE. A Scalable Database of Organ Doses for Common Diagnostic Fluoroscopy Procedures of Children: Procedures of Historical Practice for Use in Radiation Epidemiology Studies. Radiat Res. 2019 12; 192(6):649-661.
-
Gan L, Ji J, Wang L, Li QY, Zhang CF, Wang CZ, Yuan CS. Identification of the metabolites in normal and AA rat plasma, urine and feces after oral administration of Daphne genkwa flavonoids by LC-Q-TOF-MS spectrometry. J Pharm Biomed Anal. 2020 Jan 05; 177:112856.
-
Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR. A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist. 2019 09; 24(9):1151-e817.
-
Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro Oncol. 2019 01 01; 21(1):106-114.
-
Giraudet AL, Cassier PA, Iwao-Fukukawa C, Garin G, Badel JN, Kryza D, Chabaud S, Gilles-Afchain L, Clapisson G, Desuzinges C, Sarrut D, Halty A, Italiano A, Mori M, Tsunoda T, Katagiri T, Nakamura Y, Alberti L, Cropet C, Baconnier S, Berge-Montamat S, Pérol D, Blay JY. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 08; 18(1):646.
-
Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, Gomez EJ, Fischer J, Mandich H, Xiong H, Lee HJ, Munasinghe WP, Roberts-Rapp LA, Ansell PJ, Holen KD, Kumthekar P. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro Oncol. 2018 05 18; 20(6):838-847.
-
Samra GK, Intskirveli I, Govind AP, Liang C, Lazar R, Green WN, Metherate R, Mukherjee J. Development of fluorescence imaging probes for nicotinic acetylcholine a4ß2* receptors. Bioorg Med Chem Lett. 2018 02 01; 28(3):371-377.
-
Ponomarenko O, La Porte PF, Singh SP, Langan G, Fleming DEB, Spallholz JE, Alauddin M, Ahsan H, Ahmed S, Gailer J, George GN, Pickering IJ. Selenium-mediated arsenic excretion in mammals: a synchrotron-based study of whole-body distribution and tissue-specific chemistry. Metallomics. 2017 11 15; 9(11):1585-1595.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|